Triglyceride-related and eicosapentaenoic acid–mediated pathways

Triglyceride-related and eicosapentaenoic acid (EPA)–mediated pathways represent a multifaceted network of metabolic and signaling processes critical for cardiovascular homeostasis. These pathways primarily function to regulate lipid levels by decreasing the hepatic production of very-low-density lipoprotein (VLDL) and enhancing the clearance of triglycerides from the blood via the activation of lipoprotein lipase (Bhatt et al., NEJM 2019; FDA Vascepa Label). Beyond lipid modulation, EPA-mediated pathways exert significant pleiotropic effects, including the reduction of pro-inflammatory cytokines, inhibition of platelet aggregation, and stabilization of atherosclerotic plaques (Mason et al., Free Radic Biol Med 2020). These pathways are the primary therapeutic focus of purified EPA formulations, such as icosapent ethyl, which has been shown to significantly reduce major adverse cardiovascular events in high-risk patients (Bhatt et al., NEJM 2019). Unlike other omega-3 fatty acids, EPA-specific pathways do not typically result in the elevation of low-density lipoprotein (LDL) cholesterol and are associated with unique antioxidant properties within cell membranes (Sherratt et al., Chem Phys Lipids 2020). Consequently, these pathways are central to managing residual cardiovascular risk in patients with persistent hypertriglyceridemia despite statin therapy (Budoff, Am J Cardiol 2016).

Other names

EPA-mediated pathwaysTriglyceride-lowering pathwaysOmega-3 fatty acid signaling pathwaysEPA metabolic pathways

Reduction of hepatic very-low-density lipoprotein (VLDL) synthesis, enhancement of triglyceride clearance via increased lipoprotein lipase activity, and pleiotropic anti-inflammatory and antioxidant effects.